# A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

> **NCT03706040** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 172 (actual)

## Conditions studied

- Dermatitis

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Risankizumab

## Key facts

- **NCT ID:** NCT03706040
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-27
- **Primary completion:** 2020-10-28
- **Final completion:** 2021-04-26
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2021-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03706040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03706040, "A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03706040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*